• The com­pa­nies will con­tinue to col­lab­o­rate to discover and de­vel­op the next gen­er­a­tion of engi­neered alpha-beta T cells
• Editas Medicine to re­ceive a $70 million pay­ment and may be eli­gible for future mile­stone and royalty pay­ments

Cambridge, MA (Press Release) – Editas Medicine, Inc. (Nasdaq: EDIT), a lead­ing genome edit­ing com­pany, to­day an­nounced an amended col­lab­o­ration with Celgene Corpo­ra­tion (Nasdaq: CELG) under which the parties may re­search, de­vel­op, and com­mer­cial­ize au­tol­o­gous and allo­geneic alpha-beta T cell med­i­cines for the treat­ment of cancer and auto­immune dis­eases. Under the terms of the amended agree­ment, Editas Medicine will re­ceive a pay­ment of $70 million.

“Celgene is the leader in ad­vanc­ing inno­va­tive cell med­i­cines to treat blood cancers, and we are ex­cited to …

• Results Demonstrated Statistically Significant Improvement in Progression-Free Survival
• Data to be Submitted for Presentation at an Upcoming Medical Meeting

Cambridge, MA and Osaka, Japan (Press Release) – Takeda Pharma­ceu­tical Com­pany Limited (TSE: 4502/NYSE: TAK) ("Takeda") today announced the ran­dom­ized, Phase 3 TOURMALINE-MM4 study met its pri­mary end­point of pro­gres­sion free sur­vival (PFS). The trial eval­u­ated the effect of single-agent oral NIN­LARO™ (ixazomib) as a first line main­te­nance ther­apy versus placebo in adult patients diag­nosed with multiple myeloma not treated with stem cell trans­plan­ta­tion. TOURMALINE-MM4 is the first industry sponsored Phase 3 trial to explore the concept of “switch” main­te­nance, the use of med­i­cines …

Newark, CA (Press Release) – Teneobio, Inc., a clin­i­cal-stage bio­technology com­pany devel­op­ing engi­neered bispecific anti­bodies for the treat­ment of cancer announced today that it has re­ceived orphan drug desig­na­tion by the U.S. Food and Drug Admin­istra­tion (FDA) for the treat­ment of multiple myeloma.

“New and better treat­ment options are needed for multiple myeloma. While there are a number of BCMA-targeting agents cur­rently in clin­i­cal devel­op­ment, TNB-383B, an anti-BCMAxCD3 cur­rently in Phase I, is a bispecific com­prised of a unique T-cell engager designed to maximize the thera­peutic window for this class of drugs,” said …

• Ongoing Phase 1/2a Study of CD19 CAR-NK with Pivotal Study Expected to Enroll Patients in 2021
• Potential to be the First CAR Cell Therapy Approved for Outpatient Admin­istra­tion

Houston, TX and Osaka, Japan (Press Release) – The University of Texas MD Anderson Cancer Center and Takeda Pharma­ceu­tical Com­pany Limited (TSE:4502/NYSE:TAK) (“Takeda”) to­day an­nounced an ex­clu­sive license agree­ment and re­search agree­ment to de­vel­op cord blood-derived chi­meric an­ti­gen re­cep­tor-directed natural killer (CAR NK)-cell ther­a­pies, ‘armored’ with IL-15, for the treat­ment of B-cell malig­nan­cies and other cancers.

Under the agree­ment, Takeda will re­ceive access to MD Anderson’s CAR NK plat­form and the ex­clu­sive rights to de­vel­op and com­mer­cial­ize up to four pro­grams, in­clud­ing a CD19-targeted …

• Collaboration Includes Exclusive Rights and Targets for Initial Appli­ca­tions in Non-Hodgkin Lymphoma, Leukemia and Multiple Myeloma
• Notch to Receive Upfront Payment, Research Funding and an Equity Investment Plus De­vel­op­ment and Commercial Milestones and Royalties on Net Sales

South San Francisco, CA and Toronto, ON (Press Release) – Allogene Thera­peutics, Inc. (Nasdaq: ALLO), a clin­i­cal-stage bio­technology com­pany pioneering the devel­op­ment of allo­geneic CAR T (AlloCAR T™) ther­a­pies for cancer, and Notch Thera­peutics Inc., an immune cell ther­apy com­pany creating universally compatible, allo­geneic T cell ther­a­pies for the treat­ment of dis­eases of high unmet need, to­day an­nounced an ex­clu­sive world­wide col­lab­o­ration and license agree­ment to re­search and de­vel­op induced pluripotent stem cell (iPSC) AlloCAR™ ther­apy prod­ucts for initial appli­ca­tion in non-Hodgkin lym­phoma, leukemia …

Toronto, ON (Press Release) – Notch Thera­peutics, a com­pany in the emerging field of gene-modified T cell ther­apy, has been created to com­mer­cial­ize a revolutionary tech­nology that creates allo­geneic (donor) gene-edited T cells from stem cells on an industrial scale, efficiently making T cell ther­a­pies that are clin­i­cally robust and of a con­sis­tently high quality. Notch is actively pursuing industry part­ner­ships.

The founders of Notch - Sunnybrook Health Sciences Centre, University of Toronto (UoT), Toronto Innovation Acceleration Partners (TIAP) and CCRM, with Lumira Ventures as an addi­tional in­vestor - created Notch to provide …

• Companies to Collaborate on the Commercialization of XGEVA® (denosumab), KYPROLIS® (car­filz­o­mib), and BLINCYTO® (blinatumomab) in China
• Companies to Jointly Develop 20 Amgen Oncology Pipeline Assets, with BeiGene Responsible for Development and Commercialization in China as Part of the Global Development Plan
• Amgen to Purchase Approximately $2.7 Billion of BeiGene Shares
• BeiGene to Hold Analyst and Investor Call on Thursday, Octo­ber 31 at 8:00 p.m. ET

Cambridge, MA and Beijing, China (Press Release) – BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) and Amgen (NASDAQ: AMGN) today announced a global stra­te­gic on­col­ogy col­lab­o­ration for the com­mer­cial­iza­tion and devel­op­ment in China of Amgen’s XGEVA® (denosumab), KYPROLIS® (car­filz­o­mib), and BLINCYTO® (blinatumomab), and the joint global devel­op­ment of 20 on­col­ogy assets in Amgen’s pipe­line, with BeiGene responsible for devel­op­ment and com­mer­cial­iza­tion in China. In connection with the col­lab­o­ration, Amgen will purchase a 20.5% stake in BeiGene …